AtriCure Announces Commencement of Public Offering of Common Stock

  AtriCure Announces Commencement of Public Offering of Common Stock

Business Wire

WEST CHESTER, Ohio -- February 12, 2014

AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device
provider, today announced that AtriCure and certain selling stockholders
intend to offer shares of AtriCure common stock in a public offering. AtriCure
also expects to grant the underwriters a 30-day option to purchase additional
shares of its common stock to cover over-allotments, if any. AtriCure plans to
use the net proceeds from the offering for general corporate purposes and
working capital. AtriCure will not receive any proceeds from the sale of
common stock by the selling stockholders.

Piper Jaffray& Co. is acting as the sole book-running manager. Canaccord
Genuity Inc., Leerink Partners LLC, Stifel and Barrington Research Associates
are acting as co-managers for the offering.

This offering will be made pursuant to a prospectus supplement to AtriCure’s
prospectus, dated January 15, 2014, filed as part of AtriCure’s effective
$150million shelf registration statement. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy any
securities nor will there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or other jurisdiction.

Copies of the preliminary prospectus supplement and accompanying prospectus
relating to these securities may be obtained by contacting Piper Jaffray&
Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis,
MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com.

About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide.The company believes cardiothoracic surgeons are
adopting its ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects more than
5.5 million people worldwide.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or developments
that AtriCure expects, believes or anticipates will or may occur in the
future, such as those relating to AtriCure’s expectations with respect to the
proposed public offering, earnings estimates (including projections and
guidance), other predictions of financial performance, launches by AtriCure of
new products and market acceptance of AtriCure’s products. Forward-looking
statements are based on AtriCure’s experience and perception of current
conditions, trends, expected future developments and other factors it believes
are appropriate under the circumstances and are subject to numerous risks and
uncertainties, many of which are beyond AtriCure’s control. These risks and
uncertainties include the rate and degree of market acceptance of AtriCure’s
products, AtriCure’s ability to develop and market new and enhanced products,
the timing of and ability to obtain and maintain regulatory clearances and
approvals for its products, the timing of and ability to obtain reimbursement
of procedures utilizing AtriCure’s products, AtriCure’s ability to consummate
acquisitions or, if consummated, to successfully integrate acquired businesses
into AtriCure’s operations, AtriCure’s ability to recognize the benefits of
acquisitions, including potential synergies and cost savings, failure of an
acquisition or acquired company to achieve its plans and objectives generally,
risk that proposed or consummated acquisitions may disrupt operations or pose
difficulties in employee retention or otherwise affect financial or operating
results, competition from existing and new products and procedures or
AtriCure’s ability to effectively react to other risks and uncertainties
described from time to time in AtriCure’s SEC filings, such as fluctuation of
quarterly financial results, reliance on third party manufacturers and
suppliers, litigation or other proceedings, government regulation and stock
price volatility. AtriCure does not guarantee any forward-looking statement,
and actual results may differ materially from those projected. AtriCure
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. A further
list and description of risks, uncertainties and other matters can be found in
our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Contact:

AtriCure, Inc.
Andy Wade, 513-755-4564
Vice President and Chief Financial Officer
awade@atricure.com
or
Investor Relations Contact:
Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com
 
Press spacebar to pause and continue. Press esc to stop.